Table 1.

Main outcome in the RE-LY Trial.

Variable	Dabigatran 110 mg (N = 6015)	Dabigatran 150 mg (N = 6076)	Warfarin (N = 6022)	Dabigatran 110 mg vs. Warfarin		Dabigatran 150 mg vs. Warfarin
	Rate/100 person-yr	Rate/100 person-yr	Rate/100 person-yr	Relative Risk (95% CI)	P-value	Relative Risk (95% CI)	P-value
Stroke or SE	1.54	1.12	1.72	0.89 (0.73–1.09)	0.27	0.65 (0.52–0.81)	<0.001
Major bleeding	2.92	3.40	3.61	0.80 (0.70–0.93)	0.003	0.94 (0.82–1.08)	0.41
Myocardial infarction	0.82	0.81	0.64	1.29 (0.96–1.75)	0.09	1.27 (0.94–1.71)	0.12
Gastrointestinal major bleeding	1.15	1.56	1.07	1.08 (0.85–1.38)	0.52	1.48 (1.18–1.85)	0.001